|
| 37183782 | Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. | Health Technol Assess | 2023 |
| 37843101 | Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials. | Health Technol Assess | 2023 |
| 37657461 | Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. | Lancet Oncol | 2023 |
| 37716353 | The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. | Cell Rep Med | 2023 |
| 37980767 | Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Gynecol Oncol | 2023 |
| 36707610 | LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. | Sci Rep | 2023 |
| 36747644 | Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. | bioRxiv | 2023 |
| 35320352 | Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35767427 | Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma. | Anal Chem | 2022 |
| 34994606 | Multicancer Screening: One Size Does Not Fit All. | JCO Precision Oncology | 2021 |
| 34111144 | Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States. | PLoS ONE | 2021 |
| 33670571 | Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Cancers (Basel) | 2021 |
| 33991479 | Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Lancet | 2021 |
| 33648562 | UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. | Trials | 2021 |
| 33494925 | A New Era of Protein-Based Assays for Cancer Early Detection. | J Thorac Oncol | 2021 |
| 33494753 | Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. | Trials | 2021 |
| 34957977 | Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. | Tumor Biology | 2021 |
| 33051337 | Biomarkers and Strategies for Early Detection of Ovarian Cancer. | Cancer Epidemiology Biomarkers and Prevention | 2020 |
| 32145911 | Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations. | Gynecol Oncol | 2020 |
| 31714597 | Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. | Cancer | 2020 |
| 32708856 | Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. | Cancers (Basel) | 2020 |
| 33140066 | Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States. | | 2020 |
| 33012551 | Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. | Gynecol Oncol | 2020 |
| 32561125 | Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Gynecol Oncol | 2020 |
| 30967390 | Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. | Cancer Prev Res (Phila) | 2019 |
| 32337492 | Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). | JNCI Cancer Spectr | 2019 |
| 30084833 | Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. | Clin Cancer Res | 2018 |
| 28796383 | Sonographers' self-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS. | Ultrasound Obstet Gynecol | 2018 |
| 28143870 | Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. | Clin Cancer Res | 2017 |
| 28637689 | Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. | Clin Cancer Res | 2017 |
| 28742794 | The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Br J Cancer | 2017 |
| 28264823 | Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | BMJ Open | 2017 |
| 28240969 | Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. | J Clin Oncol | 2017 |
| 26573079 | Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. | J Clin Oncol | 2016 |
| 27251275 | Proteogenomics connects somatic mutations to signalling in breast cancer. | Nature | 2016 |
| 27418634 | EPIC Early Detection of Ovarian Cancer. | Clinical Cancer Research | 2016 |
| 27277878 | Squeezing more value from the analytes we have: personal baselines for multiple analytes in serial DBS. | Bioanalysis | 2016 |
| 26815306 | Protein Z: A putative novel biomarker for early detection of ovarian cancer. | Int J Cancer | 2016 |
| 27353822 | Ovarian cancer screening: UKCTOCS trial - Authors' reply. | Lancet | 2016 |
| 27206285 | Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. | Int J Gynecol Cancer | 2016 |
| 26707054 | Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Lancet | 2016 |
| 25944803 | Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. | Clin Cancer Res | 2015 |
| 25693799 | Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. | Mol Cell Proteomics | 2015 |
| 25688116 | Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. | J Natl Cancer Inst | 2015 |
| 25964255 | Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. | J Clin Oncol | 2015 |
| 25199754 | Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. | J Clin Oncol | 2014 |
| 25505814 | Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. | Dis Markers | 2014 |
| 25449569 | Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. | Gynecologic Oncology | 2014 |
| 25488086 | Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. | BJOG | 2014 |
| 24246524 | Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. | American Journal of Obstetrics and Gynecology | 2014 |